It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
modalities
Accelerating drug discovery across diverse therapeutic modalities.
Alongside our heritage in small molecules, we have amassed considerable experience and expertise in a wide range of modalities. We can advise on the best fit modality for your project and provide the most appropriate drug discovery solutions, tailored to your needs.
While small molecules remain foundational, the range of modern modalities provides a toolbox to help solve difficult drug discovery challenges.
Therapeutics now span a broad spectrum, from traditional small molecules to advanced biologics and novel modalities including PROTACs, molecular glues, Antibody Drug Conjugates (ADCs), peptides, and RNA-targeting therapies. By offering a diverse range of drug modalities, we enable our customers to address complex disease biology, overcome resistance mechanisms, and unlock new therapeutic pathways and helping advance your compound to the clinic.
Modality areas
We support a broad spectrum of therapeutic modalities to meet the diverse needs of modern drug discovery. Our cross-modality approach enables us to tackle complex disease biology, accelerate preclinical development, and deliver tailored solutions that move promising compounds towards the clinic.
Small Molecules
Small molecules remain the backbone of modern drug discovery, and they are where we began. Our heritage in small molecule research has powered decades of successful partnerships delivering novel pre-clinical and clinical candidates across a wide range of therapeutic areas.
Peptides are one of the fastest-growing therapeutic classes, bridging the gap between small molecules and biologics. We integrate chemistry, bioscience, computational design, and in vivo pharmacology to turn complex peptide ideas into real-world medicines. Our end-to-end services helps partners break through where others hit barriers.
Targeted Protein Degradation is transforming how we approach previously “undruggable” proteins. By leveraging the cell’s natural ubiquitin-proteasome system, we tag and eliminate disease-linked proteins. Our scientists are advancing this cutting-edge modality to create new treatment options for challenging targets.
Traditional ADCs offer a targeted approach to cancer treatment, combining the precision of antibodies with the potency of chemotherapy. By focusing on payload optimization to increase selectivity and efficacy, next generation ADCs offer enhanced patient benefit. Our strength in small molecule discovery means we are ideally placed to do this. Sygnature’s NewPath ADC platform brings together integrated and co-located multidisciplinary expertise to deliver more selective, high performing ADCs.
Biologics are reshaping medicine by harnessing the complexity of living systems. From monoclonal antibodies to nucleic acids and cell and gene therapies, biologics offer precise targeting and improved patient outcomes. Our bioscience, in vivo pharmacology, and DMPK teams work together to advance the next generation of biologic therapeutics, driving innovation and delivering.
Drug discovery is evolving, and so are the challenges. As global health demands rise, the need for smarter, faster, and more connected science has never been greater. Yet too often, progress is slowed by disconnection between disciplines and data.
At Sygnature Discovery, our aim is to reshape how drug discovery is delivered. Through flexible services and integrated expertise, we enable innovation at every stage. With AI and automation embedded across our workflows, we help you move faster and make confident decisions, delivering results with confidence and integrity.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Since 2011, Sygnature Discovery has delivered 60+ novel pre-clinical and 35+ clinical compounds, with its scientists named on over 200 patents. We accelerate preclinical drug discovery across a wide range of therapeutic modalities.
From small molecules and biologics to emerging technologies, our integrated and co-located approach enables partners to tackle complex disease biology with confidence. Every program is tailored, every solution is collaborative, and every step is driven by scientific integrity.
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
The concept of Targeted Protein Degradation (TPD) covers all techniques that exploit the natural mechanisms of cellular degradation to target a disease-causing protein for destruction.
